The ROE as of September 2024 (TTM) for Lexicon Pharmaceuticals, Inc. (LXRX) is 73.27%

According to Lexicon Pharmaceuticals, Inc.’s latest financial reports and current stock price. The company's current ROE is 73.27%. This represents a change of -433.46% compared to the average of -21.97% of the last 4 quarters.

Lexicon Pharmaceuticals, Inc. (LXRX) Historical ROE (quarterly & annually)

How has LXRX ROE performed in the past?

The mean historical ROE of Lexicon Pharmaceuticals, Inc. over the last ten years is -59.87%. The current 73.27% ROE has changed -222.38% with respect to the historical average. Over the past ten years (40 quarters), LXRX's ROE was at its highest in in the June 2018 quarter at 684.40%. The ROE was at its lowest in in the March 2018 quarter at -160.63%.

Lexicon Pharmaceuticals, Inc. (LXRX) ROE by Quarter and Year

Discovering the peaks and valleys of Lexicon Pharmaceuticals, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Lexicon Pharmaceuticals, Inc. (LXRX) Average ROE

How has LXRX ROE performed in the past?

The current ROE of Lexicon Pharmaceuticals, Inc. (LXRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Lexicon Pharmaceuticals, Inc. (LXRX) ROE vs. Peers

How is LXRX’s ROE compared to its peers?

Lexicon Pharmaceuticals, Inc.’s ROE is less than BioLineRx Ltd. (0%), greater than Ardelyx, Inc. (-225.62%), greater than Seres Therapeutics, Inc. (-39.73%), less than ImmunityBio, Inc. (313.56%), less than eFFECTOR Therapeutics, Inc. (100.06%), less than X4 Pharmaceuticals, Inc. (2.18%), less than Elevation Oncology, Inc. (32.93%), greater than Mereo BioPharma Group plc (-57.97%), greater than Hepion Pharmaceuticals, Inc. (-63.39%), greater than Galera Therapeutics, Inc. (-328.66%), less than Terns Pharmaceuticals, Inc. (21.95%), greater than Day One Biopharmaceuticals, Inc. (-39.58%), greater than HOOKIPA Pharma Inc. (-122.70%), greater than Enveric Biosciences, Inc. (-51.77%), greater than CohBar, Inc. (-234.16%), greater than Ocean Biomedical, Inc. (-55.32%), less than AVROBIO, Inc. (567.07%), less than null (29.68%),

Build a custom stock screener for Lexicon Pharmaceuticals, Inc. (LXRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Lexicon Pharmaceuticals, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Lexicon Pharmaceuticals, Inc. (LXRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Lexicon Pharmaceuticals, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.